(TMU) — One of the biggest challenges modern medicine has had to face is finding successful cancer treatments. And recently, treatment advances across the spectrum of cancers have continued at a rapid pace.
Lung cancer experienced significant treatment breakthroughs in 2018, primarily in immunotherapy. Other immunotherapy trials brought new treatment options to patients with a range of solid tumor and blood cancers. And also in 2018, the Nobel Prize in Physiology or Medicine was awarded to James P. Allison and Tasuku Honjo for their discovery of cancer therapy by “inhibition of negative immune regulation.”
Despite these recent big steps in medicine, pancreatic cancer—and more specifically, pancreatic ductal adenocarcinoma (PDAC)—remains a devastating diagnosis with complete surgical removal of the tumor the only chance for cure. A shocking 80-90% of patients have PDAC that is surgically incurable at the time of clinical presentation. It was estimated that 46,420 new cases and 39,590 deaths were attributable to pancreatic cancer in the United States in 2014, of which PDAC represents the vast majority.
The PJ34 molecule is a promising new treatment option against this type of cancer, as a study of a Tel Aviv University led by Prof. Malca Cohen-Armon recently found. This small molecule has the ability to induce the self-destruction of pancreatic cancer cells.
The researchers inserted xenografts—in this case, human pancreatic cancer cells— into mice whose immune systems were suppressed so they wouldn’t reject the foreign cells, and saw the cells multiply below the skin.
They then injected the molecule PJ34 into the bloodstream of the mice to see if it would affect the tumor. After 14 days there was a substantial reduction of 80% to 90% of the cancer cells. In one mouse, the tumor completely disappeared.
“This molecule causes an anomaly during the duplication of human cancer cells, provoking their rapid cell death,” said Tel Aviv University’s Cohen-Armon in a statement. “Thus, cell multiplication itself resulted in cell death in the treated cancer cells.”
Cohen-Armon added that “no adverse effects were observed and there were no changes in the weight gain of the mice, nor in their behavior.”
“The effect of a daily treatment with PJ34 provided results with higher statistical significance than those obtained by the 3 times a week treatment with PJ34. However, both treatments caused a similar massive reduction of human proteins in the tumors, 30 days after the treatment with PJ34 has been terminated,” the study reads.
While further research needs to be done in order to calculate the appropriate doses that would have to be administered to human patients in the future, this study is encouraging news. Cohen-Armon added that the team hopes to start testing the effect of the molecule on larger animals, and eventually on humans, which could take around two years, depending on funding.
Hopefully, we can make use of these huge breakthroughs in cancer research really soon.
Typos, corrections and/or news tips? Email us at [email protected]